COLL
COLLEGIUM PHARMACEUTICAL, INC
+0.28 (+1.26%)22.47USD211K成交股數732M市值18.1本益比(近四季)0.9股價營收比+6.3%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 200M+6% | 194M+9% | 205M+13% | 209M+31% | 188M+29% | 178M+23% | 182M+22% | 159M+17% | 145M | 145M | 150M | 137M |
| 營業成本 | 89.6M | 76.3M | 77.1M | 80.2M | 79.6M | 80.4M | 83.7M | 62.5M | 54.5M | 53.5M | 55.1M | 56.4M |
| 毛利 | 110M+2% | 117M+20% | 128M+31% | 129M+33% | 108M+19% | 97.3M+6% | 98.3M+4% | 96.8M+21% | 90.8M | 91.5M | 94.6M | 80.3M |
| 毛利率 | 55.2% | 60.6% | 62.5% | 61.7% | 57.7% | 54.8% | 54.0% | 60.8% | 62.5% | 63.1% | 63.2% | 58.7% |
| 研發費用 | – | – | – | – | – | – | – | – | – | – | – | – |
| 銷售管理費用 | 107M | 86.4M | 67.6M | 67.1M | 73.6M | 76.4M | 63.1M | 62.0M | 43.3M | 42.0M | 32.9M | 35.3M |
| 營業利益 | 3.7M-89% | 30.9M+42% | 60.8M+59% | 62.1M+78% | 35.1M-26% | 21.7M-56% | 38.1M-38% | 34.8M-23% | 47.5M | 49.5M | 61.7M | 45.0M |
| 營業利益率 | 1.9% | 16.0% | 29.6% | 29.7% | 18.7% | 12.2% | 20.9% | 21.9% | 32.7% | 34.1% | 41.2% | 32.9% |
| 稅後淨利 | −15.1M-226% | 14.5M+500% | 17.0M+35% | 31.5M+238% | 12.0M-39% | 2.4M-91% | 12.5M-61% | 9.3M-55% | 19.6M | 27.7M | 31.9M | 20.6M |
| 淨利率 | -7.5% | 7.5% | 8.3% | 15.0% | 6.4% | 1.4% | 6.9% | 5.9% | 13.5% | 19.1% | 21.3% | 15.1% |
| 稀釋 EPS | -0.46-235% | 0.40+471% | 0.46+28% | 0.84+211% | 0.34-35% | 0.07-90% | 0.36-56% | 0.27-49% | 0.52 | 0.71 | 0.82 | 0.53 |
| 稀釋股數 | 32.5M | 40.1M | 40.1M | 39.4M | 39.1M | 32.8M | 40.1M | 40.2M | 40.4M | 41.4M | 41.3M | 42.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 129M | 269M | 231M | 150M | 117M | 96.2M | 70.6M | 39.0M | 173M | 229M | 239M | 259M |
| 應收帳款 | 285M | 229M | 211M | 234M | 213M | 229M | 229M | 228M | 184M | 175M | 180M | 182M |
| 存貨 | 113M | 42.7M | 40.9M | 38.1M | 38.1M | 37.2M | 35.6M | 38.0M | 27.9M | 31.3M | 32.3M | 34.1M |
| 總資產 | 2.1B | 1.7B | 1.7B | 1.6B | 1.6B | 1.6B | 1.7B | 1.6B | 1.1B | 1.1B | 1.1B | 1.2B |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 1.8B | 1.3B | 1.4B | 1.3B | 1.4B | 1.4B | 1.4B | 1.4B | 837M | 892M | 948M | 999M |
| 股東權益 | 312M | 312M | 302M | 275M | 232M | 234M | 229M | 234M | 217M | 222M | 195M | 179M |
| 負債比 | 85.4% | 81.1% | 81.8% | 82.9% | 85.4% | 85.6% | 86.2% | 85.7% | 79.4% | 80.1% | 82.9% | 84.8% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 57.1M+3% | – | – | – | 55.4M-11% | – | – | – | 61.9M | – | – |
| 資本支出 | – | 270K | – | – | – | 798K | – | – | – | 568K | – | – |
| 自由現金流 | – | 56.8M+4% | – | – | – | 54.6M-11% | – | – | – | 61.4M | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | 0.00 | – | – | – | 25.1M | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 29.4% | – | – | – | 30.7% | – | – | – | 42.3% | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 781M
| Single Reportable | 781M | 100.0% | +23.6% |
|---|
產品／服務2025 年度 · 781M
| Belbuca | 222M | 28.4% | +4.9% |
|---|---|---|---|
| Xtampza ER | 199M | 25.5% | +4.2% |
| Jornay Pm | 149M | 19.1% | +299.7% |
| Nucynta IR | 115M | 14.8% | +14.5% |
| Nucynta ER | 81.0M | 10.4% | +6.9% |
| Symproic And Other | 14.5M | 1.9% | -4.3% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 781M | +23.6% | 63.0M | 8.1% | 1.73 | 328M |
| FY2024 | 631M | +11.4% | 69.0M | 10.9% | 1.86 | 203M |
| FY2023 | 567M | +22.2% | 48.0M | 8.5% | 1.29 | 274M |
| FY2022 | 464M | +67.6% | −25.0M | -5.4% | -0.74 | 123M |
| FY2021 | 277M | -10.7% | 72.0M | 26.0% | 1.86 | 102M |
| FY2020 | 310M | +4.5% | 26.8M | 8.6% | 0.76 | 88.4M |
| FY2019 | 297M | +5.8% | −22.7M | -7.7% | -0.68 | 21.3M |
| FY2018 | 280M | – | −39.1M | -14.0% | -1.19 | 164M |